Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field - Seite 2

"The acquisition of Quirem Medical further strengthens our business, expands on
our manufacturing and clinical development activities, and complements our
comprehensive suite of offerings to support our customers, " said Jim Rushworth,
Chief Commercial Officer of the Interventional Systems Division of Terumo.

Using Quirem's innovative Holmium-166 platform technology, physicians are
further empowered to drive treatment outcomes after SIRT. "By adding the
Holmium-166 platform to our existing IO portfolio, we will further contribute to
giving liver cancer patients a better future," said Laurent Domas, Vice
President, Global Interventional Oncology Strategy & Therapy Development, Terumo
Europe. "This acquisition reflects Terumo's commitment to build a broad platform
of loco-regional treatment options for liver cancer and is another step forward
as we aim to develop and provide treatment solutions for other organs as well."

"We are very excited with the acquisition of Quirem Medical by Terumo as it will
further drive the adoption of our unique product offerings worldwide and
accelerate our pace of innovation, reaching more patients that will benefit from
our technology," said Jan Sigger, CEO of Quirem Medical.

The global interventional oncology market value is more than USD 1 billion,
which is a rapidly growing field with a CAGR of 7%. Within this field, SIRT is
one of the main treatments that is expected to help to drive this growth year on
year.

Terumo has been building its presence in the interventional oncology field, with
product offerings such as the micro catheter system (Progreat(TM)), compressible
microspheres for embolization (HydroPearl(TM)), drug-eluting microspheres
(LifePearl(TM)), and biodegradable drug eluting microspheres (BioPearl(TM)). In
2015, Terumo invested in Quirem Medical and became the exclusive global
distributor of their technology.

About Quirem Medical B.V.

Quirem Medical develops and commercializes the next-generation Selective
Internal Radiation Therapy (SIRT) microspheres based on the radioisotope
Holmium-166. The company believes the treatment outcome of unresectable liver
cancer with SIRT can be optimized with Holmium-166 microspheres, which can be
visualized and quantified to improve SIRT patient selection, treatment planning
and treatment verification. Its innovative Holmium-166 platform technology
provides physicians a complete CE-marked SIRT solution including
QuiremScout(TM), QuiremSpheres(TM) and the supporting dosimetry software
Q-Suite(TM). The company is based in Deventer, the Netherlands and has
approximately 30 employees.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been
committed to "Contributing to Society through Healthcare" for nearly 100 years.
Based in Tokyo and operating globally, Terumo employs more than 25,000
associates worldwide to provide innovative medical solutions in more than 160
countries and regions. The company started as a Japanese thermometer
manufacturer and has been supporting healthcare ever since. Now, its extensive
business portfolio ranges from vascular intervention and cardio-surgical
solutions, blood transfusion and cell therapy technology, to medical products
essential for daily clinical practice. Terumo will further strive to be of value
to patients, medical professionals, and society at large.

Logo - https://mma.prnewswire.com/media/1214359/Terumo_Logo.jpg

Additional content: http://presseportal.de/pm/146437/4652163
OTS: Terumo